An interventional trial testing IL-1 blockade (Anakinra) in ACD is registered (NCT05498467), and CXCR2 antagonists have been evaluated in several clinical trials against neutrophil-driven implications (for example COPD/bronchiectasis and oncology studies) [98,99,100,101,102], but, to our knowledge, not yet in randomized trials for ACD. The gene discussed is IL1A; the disease is granular corneal dystrophy type II.